UM

Browse/Search Results:  1-10 of 40 Help

Selected(0)Clear Items/Page:    Sort:
Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer Journal article
EUROPEAN JOURNAL OF PHARMACOLOGY, 2018,Volume: 838,Page: 41-52
Authors:  Yang, Zheng;  Zhang, Shao-Lin;  Hu, Xiaohui;  Tam, Kin Yip
Favorite  |  View/Download:12/0  |  Submit date:2018/10/30
Dichloroacetophenone  Epidermal growth factor receptor  Tyrosine kinase inhibitor  Synergism  Hypoxia  Oxidative phosphorylation  
Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway Journal article
Oncotarget, 2018,Volume: 9,Issue: 62,Page: 31958-31970
Authors:  Nana Ai;  Cheong-Meng Chong.;  Weiting Chen;  Zhe Hu;  Huanxing Su;  Guokai Chen;  Queenie Wing Lei Wong;  Wei Ge
Favorite  |  View/Download:7/0  |  Submit date:2018/12/11
Angiogenesis  Enos  Huvec  Mapk  Ponatinib  
A novel Ca2+ current blocker promotes angiogenesis and cardiac healing after experimental myocardial infarction in mice Journal article
PHARMACOLOGICAL RESEARCH, 2018,Volume: 134,Page: 109-117
Authors:  Cui, Guozhen;  Xin, Qiqi;  Tseng, Hisa Hui Ling;  Hoi, Maggie PuiMan;  Wang, Yan;  Yang, Binrui;  Choi, InLeng;  Wang, Yuqiang;  Yuan, Rong;  Chen, Keji;  Cong, Weihong;  Lee, Simon MingYuen
View  |  Adobe PDF(3018Kb)  |  Favorite  |  View/Download:104/3  |  Submit date:2018/10/30
Cardioprotection  Angiogenesis  ADTM  Zebrafish  VEGF  
Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells Journal article
EUROPEAN JOURNAL OF PHARMACOLOGY, 2018,Volume: 830,Page: 17-25
Authors:  Zhang, Le-Le;  Feng, Zhe-Ling;  Su, Min-Xia;  Jiang, Xiao-Ming;  Chen, Xiuping;  Wang, Yitao;  Li, Ao;  Lin, Li-Gen;  Lu, Jin-Jian
View  |  Adobe PDF(3226Kb)  |  Favorite  |  View/Download:155/21  |  Submit date:2018/10/30
Nagilactone e  Non-small Cell Lung Cancer  Cyclin B1  Cell Cycle  Apoptosis  
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies Journal article
CANCER LETTERS, 2018,Volume: 420,Page: 242-246
Authors:  Tang, Zheng-Hai;  Lu, Jin-Jian
Favorite  |  View/Download:9/0  |  Submit date:2018/10/30
Osimertinib  Azd9291  Egfr Tki  Resistant Mechanisms  Therapeutic Strategies  
Increased expression of IRE1α associates with the resistant mechanism of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells Journal article
Anti-Cancer Agents in Medicinal Chemistry, 2018,Volume: 18,Issue: 4,Page: 550-555
Authors:  Tang Z.-H.;  Su M.-X.;  Guo X.;  Jiang X.-M.;  Jia L.;  Chen X.;  Lu J.-J.
Favorite  |  View/Download:3/0  |  Submit date:2018/12/28
Azd9291  Egfr  Ire1α  Lune Cancer  Nsclc  Osimertinib  
Substantial protection against MPTP-associated Parkinson's neurotoxicity in vitro and in vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B Journal article
Neuropharmacology, 2017,Volume: 126,Page: 12-24
Authors:  Guo B.;  Hu S.;  Zheng C.;  Wang H.;  Luo F.;  Li H.;  Cui W.;  Yang X.;  Cui G.;  Mak S.;  Choi T.C.-L.;  Ma E.D.-L.;  Wang Y.;  Lee S.M.Y.;  Zhang Z.;  Han Y.
Favorite  |  View/Download:3/0  |  Submit date:2018/11/06
Monoamine oxidase-B  Myocyte enhancer factor 2D  Neuroprotection  Parkinson's disease  SU4312  
Substantial protection against MPTP-associated Parkinson's neurotoxicity in vitro and in vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B Journal article
Neuropharmacology, 2017,Volume: 126,Page: 12-24
Authors:  Guo B.;  Hu S.;  Zheng C.;  Wang H.;  Luo F.;  Li H.;  Cui W.;  Yang X.;  Cui G.;  Mak S.;  Choi T.C.-L.;  Ma E.D.-L.;  Wang Y.;  Lee S.M.Y.;  Zhang Z.;  Han Y.
Favorite  |  View/Download:3/0  |  Submit date:2018/11/06
Monoamine oxidase-B  Myocyte enhancer factor 2D  Neuroprotection  Parkinson's disease  SU4312  
Substantial protection against MPTP-associated Parkinson's neurotoxicity in vitro and in vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B Journal article
NEUROPHARMACOLOGY, 2017,Volume: 126,Page: 12-24
Authors:  Guo, Baojian;  Hu, Shengquan;  Zheng, Chengyou;  Wang, Hongyu;  Luo, Fangcheng;  Li, Haitao;  Cui, Wei;  Yang, Xifei;  Cui, Guozhen;  Mak, Shinghung;  Choi, Tony Chung-Lit;  Ma, Edmond Dik-Lung;  Wang, Yuqiang;  Lee, Simon Ming Yuen;  Zhang, Zaijun;  Han, Yifan
Favorite  |  View/Download:9/0  |  Submit date:2018/10/30
Parkinson's disease  SU4312  Neuroprotection  Myocyte enhancer factor 2D  Monoamine oxidase-B  
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells Journal article
ACTA PHARMACOLOGICA SINICA, 2017,Volume: 38,Issue: 11,Page: 1512-1520
Authors:  Jiang, Xiao-Ming;  Xu, Yu-Lian;  Huang, Mu-Yang;  Zhang, Le-Le;  Su, Min-Xia;  Chen, Xiuping;  Lu, Jin-Jian
Favorite  |  View/Download:15/0  |  Submit date:2018/10/30
Non-small Cell Lung Cancer  Egfr  Osimertinib  Pd-l1  Ubiquitin-proteasome System  Mg-132  Bortezomib  Gsk3 Beta  Licl